When stratifying patients according to their liver involvement, we found that NASH patients displayed a significantly higher expression of hepatic TLR6 compared to patients with normal liver biopsy, but no differences were found between NAFL and NASH patients (Figure 2B). Here, TLR6 is linked to metabolic dysfunction-associated steatohepatitis.